Hologic (NASDAQ:HOLX) Cut to Hold at Leerink Partnrs

Hologic (NASDAQ:HOLX) was downgraded by stock analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

Several other research analysts also recently weighed in on HOLX. Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Stephens reiterated an “overweight” rating and set a $84.00 price target on shares of Hologic in a research note on Thursday. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $80.00 to $75.00 in a research report on Thursday. Raymond James restated an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Ten analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Performance

Shares of HOLX stock opened at $64.58 on Thursday. Hologic has a 12 month low of $63.88 and a 12 month high of $84.67. The firm has a market cap of $14.58 billion, a PE ratio of 19.39, a P/E/G ratio of 2.35 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company’s fifty day simple moving average is $72.33 and its 200-day simple moving average is $77.76.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Equities research analysts expect that Hologic will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

A number of institutional investors have recently made changes to their positions in HOLX. Benson Investment Management Company Inc. acquired a new position in shares of Hologic in the 4th quarter valued at $4,832,000. Clean Yield Group increased its position in shares of Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 582 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares during the last quarter. Finally, Versor Investments LP purchased a new position in Hologic during the third quarter worth approximately $1,677,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.